Citius Pharmaceuticals Management
Management criteria checks 2/4
Citius Pharmaceuticals' CEO is Leonard Mazur, appointed in Mar 2016, has a tenure of 8.75 years. total yearly compensation is $1.98M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $45.60K. The average tenure of the management team and the board of directors is 3.9 years and 8.6 years respectively.
Key information
Leonard Mazur
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 24.0% |
| CEO tenure | 8.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully
Apr 06
We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate
Dec 08Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?
Aug 01We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Apr 12Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation
Dec 25Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK
Sep 28Citius Pharmaceuticals GAAP EPS of -$0.06
Aug 11Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely
Aug 05Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK
Jul 12Citius Pharmaceuticals: Hoping For A Turnaround Strategy
Jul 05Critical Care Biopharma - Citius Pharmaceuticals
Apr 13Citius: 2022 Is A Year Of Catalysts
Mar 28We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
Dec 04Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization
Sep 26Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth
Aug 28Citius: Halt For Superiority On The Horizon
Jun 15We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth
May 15Citius Pharmaceuticals shares rise in anticipation of Mino-Lok phase 3 results
Apr 26Is Citius Pharmaceuticals (NASDAQ:CTXR) In A Good Position To Deliver On Growth Plans?
Dec 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$37m |
| Dec 31 2023 | n/a | n/a | -US$39m |
| Sep 30 2023 | US$2m | US$475k | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$31m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | n/a | n/a | -US$28m |
| Sep 30 2022 | US$1m | US$400k | -US$34m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | n/a | n/a | -US$26m |
| Sep 30 2021 | US$788k | US$348k | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$24m |
| Mar 31 2021 | n/a | n/a | -US$21m |
| Dec 31 2020 | n/a | n/a | -US$21m |
| Sep 30 2020 | US$550k | US$250k | -US$18m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$17m |
| Dec 31 2019 | n/a | n/a | -US$16m |
| Sep 30 2019 | US$473k | US$250k | -US$16m |
| Jun 30 2019 | n/a | n/a | -US$15m |
| Mar 31 2019 | n/a | n/a | -US$12m |
| Dec 31 2018 | n/a | n/a | -US$13m |
| Sep 30 2018 | US$398k | US$250k | -US$13m |
Compensation vs Market: Leonard's total compensation ($USD1.98M) is above average for companies of similar size in the US market ($USD650.00K).
Compensation vs Earnings: Leonard's compensation has increased whilst the company is unprofitable.
CEO
Leonard Mazur (79 yo)
8.8yrs
Tenure
US$1,981,113
Compensation
Mr. Leonard L. Mazur is Chairman, Chief Executive Officer & President of Citius Oncology, Inc. from August 12, 2024. Mr. Mazur has been Chief Executive Officer of Citius Pharmaceuticals, Inc. since May 01,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 8.8yrs | US$1.98m | 0.19% $ 45.6k | |
| Co-Founder & Executive Vice Chairman | 9.2yrs | US$1.59m | 1.03% $ 249.4k | |
| Executive VP & Chief Medical Officer | 4.4yrs | US$1.17m | 0% $ 0 | |
| Chief Business Officer | 7.1yrs | US$809.00k | 0.031% $ 7.6k | |
| Executive Vice President of Operations | 8.8yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP and Head of Clinical Operations & Quality Assurance | 2.8yrs | no data | no data | |
| Senior Vice President of Business Strategy | 3.9yrs | no data | no data | |
| Executive Vice President of Chemistry | 3.1yrs | no data | no data | |
| Executive Vice President of Quality Assurance | 1.9yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs | 1.3yrs | no data | no data |
3.9yrs
Average Tenure
69.5yo
Average Age
Experienced Management: CTXR's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.3yrs | US$1.98m | 0.19% $ 45.6k | |
| Co-Founder & Executive Vice Chairman | 9.2yrs | US$1.59m | 1.03% $ 249.4k | |
| Independent Director | 1.8yrs | US$150.13k | 0% $ 0 | |
| ARDS Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 9.2yrs | US$196.97k | 0% $ 0 | |
| Independent Director | 8.8yrs | US$190.97k | 0.0061% $ 1.5k | |
| Independent Director | 8.5yrs | US$190.97k | 0.0012% $ 297.5 | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 6.4yrs | no data | no data | |
| ARDS Scientific Advisory Board Member | 3.5yrs | no data | no data | |
| ARDS Scientific Advisory Board Member | no data | no data | no data |
8.6yrs
Average Tenure
77yo
Average Age
Experienced Board: CTXR's board of directors are considered experienced (8.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:53 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Citius Pharmaceuticals, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Jason Kolbert | H.C. Wainwright & Co. |
| Vernon Bernardino | H.C. Wainwright & Co. |